ANITA OBENG: Open Payments
NPI 1093486417 · CRANSTON, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,812 in 138 payments from 16 companies in 2025. Trend: 2023 $2,440 · 2024 $2,037 · 2025 $2,812
Food & beverage: $2,812
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $535 |
| Otsuka America Pharmaceutical, Inc. | 32 | $480 |
| Vanda Pharmaceuticals Inc. | 19 | $413 |
| Alkermes, Inc. | 9 | $228 |
| Janssen Pharmaceuticals, Inc | 4 | $226 |
| Lundbeck LLC | 15 | $215 |
| Axsome Therapeutics, Inc. | 6 | $139 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $135 |
| Teva Pharmaceuticals USA, Inc. | 4 | $93 |
| Neurocrine BioSciences, Inc. | 3 | $79 |
Products named: VRAYLAR, REXULTI, FANAPT, SPRAVATO, ARISTADA, ABILIFY ASIMTUFII, Auvelity, CAPLYTA.
Industry payments across RI — which companies pay providers there.
